3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Melanoma
50
Carcinoma, Non-Small-Cell Lung
50
Carcinoma, Renal Cell
37
Carcinoma, Hepatocellular
20
Neoplasm Metastasis
19
Lung Neoplasms
19
Neoplasms
17
Squamous Cell Carcinoma of Head and Neck
16
Stomach Neoplasms
15
Colorectal Neoplasms
15
Carcinoma, Transitional Cell
14
Adenocarcinoma Of Esophagus
12
Prostatic Neoplasms
10
Hodgkin Disease
10
Brain Neoplasms
10
Urinary Bladder Neoplasms
8
Ovarian Neoplasms
8
Multiple Myeloma
8
Triple Negative Breast Neoplasms
7
Rectal Neoplasms
7
Pancreatic Neoplasms
7
Esophageal Neoplasms
7
Breast Neoplasms
7
Colonic Neoplasms
6
Clear-cell metastatic renal cell carcinoma
6
Carcinoma, Basal Cell
6
Uveal Melanoma
5
Uterine Cervical Neoplasms
5
Thyroid Neoplasms
5
Sarcoma
5
Interventions
Docetaxel
2
Cisplatin
2
130-nm albumin-bound paclitaxel
2
taxane
1
liposomal doxorubicin
1
durvalumab
1
cemiplimab
1
atezolizumab
1
Pemetrexed
1
Paclitaxel
1
Nivolumab
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Biosimilar Pharmaceuticals
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Vaccinia
×
Nivolumab
×
90 days
×
Clear all
NCT06463665
2026-06-04
VIRO-25
Genelux Corporation
Phase 2
Recruiting
142 enrolled